How High Can Copper Go?
To power the green revolution, copper demand continues to skyrocket with no end in sight. Prices hit a 10-year high; as copper jumped 79% in the past year. Some analysts are calling for copper to rise another 50-100%! We may be at the beginning of a copper bull run the likes we've never seen before. Just how high can copper go?
Find Out in this Research Report.
Saurabh Saha, insider at Centessa Pharmaceuticals

Saurabh Saha Insider Information

Dr. Saurabh Saha, MD, PhD, is Chief Executive Officer and a member of the Board of Directors of Centessa Pharmaceuticals. Most recently, as Senior Vice President of Research & Development at Bristol Myers Squibb Company, Saurabh led translational medicine across all therapeutic areas spanning discovery, early development through late development, and commercialization. In 2019, he led the Research & Development diligence in the acquisition of Celgene by BMS and subsequently managed key aspects of the integration across both organizations. During his tenure, Saurabh laid the foundation for the BMS Research & Development headquarters in Cambridge, Massachusetts, USA serving as site head and establishing a research focus on discovering new cancer treatments for immunotherapy resistance.

Previously, Saurabh was a Venture Partner at Atlas Venture where he held leadership positions with several portfolio biotech companies, including Chief Medical Officer of Synlogic, and Chief Executive Officer of Delinia until its sale to Celgene in early 2017.

In 2008, he established the translational research and development organization at BioMed Valley Discoveries where he served as Chief Scientific Officer and later President and was responsible for leading the development and demonstrating human effectiveness of two first-in-class cancer therapies.

Earlier in his career, Saurabh was a Management Consultant in the pharmaceutical practice at McKinsey & Company and subsequently appointed Director and Head of the New Indications Discovery Unit at Novartis. He is on the editorial boards of several medical journals and is an Associate Member and Global Clinical scholar at Harvard Medical School.

Saurabh holds an MD and PhD in cancer genetics from The Johns Hopkins School of Medicine, where he completed his graduate studies in Bert Vogelstein’s lab. He is an alumnus of Harvard Business School and Oxford University, studying General Management and Biophysics respectively. Saurabh received a BSc in Biochemistry from the California Institute of Technology (Caltech).

What is Saurabh Saha's net worth?

The estimated net worth of Saurabh Saha is at least $180,500.00 as of June 24th, 2022. Dr. Saha owns 38,000 shares of Centessa Pharmaceuticals stock worth more than $180,500 as of August 11th. This net worth estimate does not reflect any other investments that Dr. Saha may own. Additionally, Dr. Saha receives a salary of $987,210.00 as CEO at Centessa Pharmaceuticals. Learn More about Saurabh Saha's net worth.

How old is Saurabh Saha?

Dr. Saha is currently 45 years old. There are 7 older executives and no younger executives at Centessa Pharmaceuticals. Learn More on Saurabh Saha's age.

What is Saurabh Saha's salary?

As the CEO of Centessa Pharmaceuticals plc, Dr. Saha earns $987,210.00 per year. Learn More on Saurabh Saha's salary.

How do I contact Saurabh Saha?

The corporate mailing address for Dr. Saha and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at [email protected] Learn More on Saurabh Saha's contact information.

Has Saurabh Saha been buying or selling shares of Centessa Pharmaceuticals?

Saurabh Saha has not been actively trading shares of Centessa Pharmaceuticals over the course of the past ninety days. Most recently, on Friday, June 24th, Saurabh Saha bought 10,000 shares of Centessa Pharmaceuticals stock. The stock was acquired at an average cost of $4.63 per share, with a total value of $46,300.00. Following the completion of the transaction, the chief executive officer now directly owns 38,000 shares of the company's stock, valued at $175,940. Learn More on Saurabh Saha's trading history.

Who are Centessa Pharmaceuticals' active insiders?

Centessa Pharmaceuticals' insider roster includes Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), David Grainger (Insider), Aaron Kantoff (Director), and Saurabh Saha (CEO). Learn More on Centessa Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Centessa Pharmaceuticals?

In the last year, Centessa Pharmaceuticals insiders bought shares 11 times. They purchased a total of 280,500 shares worth more than $3,235,137.92. In the last year, insiders at the sold shares 5 times. They sold a total of 68,945 shares worth more than $342,214.59. The most recent insider tranaction occured on August, 1st when EVP Antoine Yver sold 10,423 shares worth more than $46,382.35. Insiders at Centessa Pharmaceuticals own 9.1 % of the company. Learn More about insider trades at Centessa Pharmaceuticals.

Information on this page was last updated on 8/1/2022.

Saurabh Saha Insider Trading History at Centessa Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/24/2022Buy10,000$4.63$46,300.0038,000View SEC Filing Icon  
2/2/2022Buy5,000$9.74$48,700.00View SEC Filing Icon  
11/16/2021Buy23,000$12.28$282,440.00View SEC Filing Icon  
See Full Table

Saurabh Saha Buying and Selling Activity at Centessa Pharmaceuticals

This chart shows Saurabh Saha's buying and selling at Centessa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Centessa Pharmaceuticals Company Overview

Centessa Pharmaceuticals logo
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Read More

Today's Range

Now: $4.35
Low: $4.27
High: $4.81

50 Day Range

MA: $4.65
Low: $3.18
High: $5.91

2 Week Range

Now: $4.35
Low: $2.88
High: $25.98

Volume

591 shs

Average Volume

136,702 shs

Market Capitalization

$409.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo?
Communist China has the USA in a resource stranglehold. They have a monopoly on this CRITICAL metal that we desperately need for military technology. In fact, both Trump AND Biden passed executive orders that addressed this crisis. And it could have a massive effect on smart investor's bank accounts.
See This Growing National Security Threat Here